AIRSAirsculpt Technologies, Inc.(AIRS)Stock Analysis

AI analysis on 2,800+ stocks →
HealthcareNasdaqsmall
Institutional-grade research for retail investors
SEC EDGAR: CIK 1870940AIRS stock profile & AI dashboard →

13F Pro Quality Score

31.1/100

Rank #2,468 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

6.7/100

Profitability

26.6/100

Balance Sheet

21.9/100

Earnings Quality

58.2/100

Free Cash Flow

40.6/100

Institutional Flow

79.6/100

Revenue Scale

20.2/100

Dilution Risk

45.8/100
Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

AIRS Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Airsculpt Technologies, Inc. (AIRS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AIRS at 31.1/100 on a 32-signal composite quality model, placing it at rank #2,468 of 2,962 stocks — the bottom half of the AI-ranked universe. AIRS scores in the top quartile across institutional flow (79.6). Areas of concern include revenue growth (6.7) and revenue scale (20.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 45.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Airsculpt Technologies, Inc. reports quarterly revenue of $39.4M, net income of $-2.4M, an operating margin of -4.6%. Top institutional holders of AIRS by reported 13-F value include Vesey Street Capital Partners, L.L.C., THRIVENT FINANCIAL FOR LUTHERANS, BlackRock, based on the most recent SEC filings. AIRS trades on the Nasdaq exchange and files with the SEC under CIK 1870940. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AIRS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Airsculpt Technologies, Inc. directly from SEC EDGAR. Airsculpt Technologies, Inc.'s 13F Pro composite quality score has ranged between 25 and 56 since 2022, currently 31.1 — a declining long-term trajectory across 62 quarterly and live scoring snapshots.

Fun facts about Airsculpt Technologies, Inc.

Quirks, history, and lore behind AIRS — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    U.S. healthcare company · listed on Nasdaq · headquartered in Florida · operates in the elective medical procedures space.
  • 2
    The Numbers
    A small-cap company with annual revenue in the range of roughly $200 million, operating a growing network of outpatient surgical centers across the U.S.
  • 3
    The History
    Founded in the 2010s, the company commercialized a proprietary minimally invasive body contouring technique and went public on Nasdaq in 2021.
  • 4
    The Secret
    Unlike traditional liposuction performed in hospitals, its procedure is done under local anesthesia only — patients are awake the whole time and walk out the same day.
  • 5
    The Lore
    The company's proprietary technology uses powered cannulas to remove fat more precisely than conventional methods, and it fiercely guards its patented surgical approach as its core moat.
  • 6
    The Giveaway
    Its very name tells you what it does: sculpting bodies with air-powered tools — this cosmetic fat-removal company's ticker even spells out its breezy ambitions.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$39.4M

Net Income

Q1 2026

$-2.4M

Free Cash Flow

Q1 2026

$5.2M

Operating Margin

Q1 2026

-4.6%

ROIC

Q1 2026

-4.8%

D/E Ratio

Q1 2026

0.50

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-15.8% YoY
$151.8MFY 2025
FY22 $168.8MFY23 $195.9MFY24 $180.3MFY25 $151.8M

Net Income

-45.5% YoY
$-11.7MFY 2025
FY22 $-14.7MFY23 $-4.2MFY24 $-8.0MFY25 $-11.7M

Operating Income

-630.3% YoY
$-11.6MFY 2025
FY22 $-4.5MFY23 $9.7MFY24 $-1.6MFY25 $-11.6M

EPS (Diluted)

-35.7% YoY
$-0.19FY 2025
FY22 $-0.26FY23 $-0.08FY24 $-0.14FY25 $-0.19

Total Assets

-12.0% YoY
$187.3MFY 2025
FY22 $200.8MFY23 $204.0MFY24 $212.8MFY25 $187.3M

Total Debt

-16.8% YoY
$61.5MFY 2025
FY22 $85.7MFY23 $73.8MFY24 $74.0MFY25 $61.5M

Op. Cash Flow

-72.7% YoY
$3.1MFY 2025
FY22 $24.4MFY23 $24.0MFY24 $11.3MFY25 $3.1M

Free Cash Flow

+126.0% YoY
$692.0KFY 2025
FY22 $11.5MFY23 $14.0MFY24 $-2.7MFY25 $692.0K

Get alerted when AIRS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Airsculpt Technologies, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Companies Similar to AIRS

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

CPIX

CUMBERLAND PHARMACEUTICALS INC

27
AI score
Similar quality profile · 1 shared holders
STLN

Starling Oncology, Inc.

44
AI score
Similar quality profile · 7 shared holders
XGN

EXAGEN INC.

29
AI score
Similar quality profile · 5 shared holders
ORGO

Organogenesis Holdings Inc.

30
AI score
Similar quality profile
EBS

Emergent BioSolutions Inc.

32
AI score
Similar quality profile · 1 shared holders
MAZE

Maze Therapeutics, Inc.

24
AI score
Similar quality profile · 2 shared holders
PTHS

Pelthos Therapeutics Inc.

18
AI score
Similar quality profile · 2 shared holders
STIM

Neuronetics, Inc.

27
AI score
Similar quality profile · 5 shared holders

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

Put AIRS on your watchlist

Track score changes the day Airsculpt Technologies, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is AIRS a good stock to buy?

13F Pro's AI-powered analysis of Airsculpt Technologies, Inc. (AIRS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AIRS are available on the AIRS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. AIRS is classified as a small company.

Which hedge funds own AIRS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AIRS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Airsculpt Technologies, Inc.'s investment landscape.